Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 747 results
Found 747 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

S

Schooley RT, Spritzler J, Wang H, et al. "AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein." J. Infect. Dis.. 2010;202(5):705-16.
Schouten JThomas, Schiffer JT. "Equal HIV-1 decay kinetics in HSV-2-infected and HSV-2-uninfected clinical trial participants treated with antiretroviral therapy." J. Acquir. Immune Defic. Syndr.. 2012;60(1):68-71.
Schouten JT, Krambrink A, Ribaudo HJ, et al. "Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095." Clin. Infect. Dis.. 2010;50(5):787-91.
Schwarze-Zander C, Blackard JT, Zheng H, et al. "GB virus C (GBV-C) infection in hepatitis C virus (HCV)/HIV-coinfected patients receiving HCV treatment: importance of the GBV-C genotype." J. Infect. Dis.. 2006;194(4):410-9.
Seaman WT, Andrews E, Couch M, et al. "Detection and quantitation of HPV in genital and oral tissues and fluids by real time PCR." Virol. J.. 2010;7:194.
Sereti I, Dunham RM, Spritzler J, et al. "IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection." Blood. 2009;113(25):6304-14.
Servoss JC, Kitch DW, Andersen JW, Reisler RB, Chung RT, Robbins GK. "Predictors of antiretroviral-related hepatotoxicity in the adult AIDS Clinical Trial Group (1989-1999)." J. Acquir. Immune Defic. Syndr.. 2006;43(3):320-3.
Sha BE, Tierney C, Sun X, et al. "PHARMACOKINETIC EXPOSURE AND VIROLOGIC RESPONSE IN HIV-1 INFECTED PREGNANT WOMEN TREATED WITH LOPINAVIR/RITONAVIR: AIDS CLINICAL TRIALS GROUP PROTOCOL A5153S: A SUBSTUDY TO A5150." Jacobs J AIDS HIV. 2015;1(1).
Sha BE, Tierney C, Cohn SE, et al. "Postpartum viral load rebound in HIV-1-infected women treated with highly active antiretroviral therapy: AIDS Clinical Trials Group Protocol A5150." HIV Clin Trials. 2011;12(1):9-23.
Shafer RW. "Rationale and uses of a public HIV drug-resistance database." J. Infect. Dis.. 2006;194 Suppl 1:S51-8.
Shaffer D, Hughes MD, Sawe F, et al. "Cardiovascular disease risk factors in HIV-infected women after initiation of lopinavir/ritonavir- and nevirapine-based antiretroviral therapy in Sub-Saharan Africa: A5208 (OCTANE)." J. Acquir. Immune Defic. Syndr.. 2014;66(2):155-63.
Shah, iv S, Mildvan D. "HIV and aging." Curr Infect Dis Rep. 2006;8(3):241-7.
Sharaf R, Lee GQ, Sun X, et al. "HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers." J. Clin. Invest.. 2018;128(9):4074-4085.
Sharif M, Daryani A, Karimi SA. "A faunistic survey of cercariae isolated from lymnaeid snails in central areas of Mazandaran, Iran." Pak. J. Biol. Sci.. 2010;13(4):158-63.
Sharkey M, Babic DZ, Greenough T, Gulick R, Kuritzkes DR, Stevenson M. "Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure." PLoS Pathog.. 2011;7(2):e1001303.
Sherman KE, Kang M, Sterling R, et al. "Phase 3 trial of first generation protease inhibitor therapy for hepatitis C virus/human immunodeficiency virus coinfection." World J Hepatol. 2017;9(4):217-223.
Sherman KE, Andersen JW, Butt AA, et al. "Sustained long-term antiviral maintenance therapy in HCV/HIV-coinfected patients (SLAM-C)." J. Acquir. Immune Defic. Syndr.. 2010;55(5):597-605.
Sherman KE, Rouster SD, Stanford S, et al. "Hepatitis C virus (HCV) quasispecies complexity and selection in HCV/HIV-coinfected subjects treated with interferon-based regimens." J. Infect. Dis.. 2010;201(5):712-9.
Sherman KE, Rouster SD, Kang M, Umbleja T, Sterling R, Butt AA. "PNPLA3 Gene Polymorphisms in HCV/HIV-Coinfected Individuals." Dig. Dis. Sci.. 2018.
Shiboski CH, Lee A, Chen H, et al. "Human papillomavirus infection in the oral cavity of HIV patients is not reduced by initiating antiretroviral therapy." AIDS. 2016;30(10):1573-82.
Shiboski CH, Chen H, Secours R, et al. "High Accuracy of Common HIV-Related Oral Disease Diagnoses by Non-Oral Health Specialists in the AIDS Clinical Trial Group." PLoS ONE. 2015;10(7):e0131001.
Shiboski CH, Chen H, Ghannoum MA, et al. "Role of oral candidiasis in TB and HIV co-infection: AIDS Clinical Trial Group Protocol A5253." Int. J. Tuberc. Lung Dis.. 2014;18(6):682-8.
Shikuma CM, Yang Y, Glesby MJ, et al. "Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095)." J. Acquir. Immune Defic. Syndr.. 2007;44(5):540-50.
Shikuma CM, Gangcuangco LMar A, Killebrew DA, et al. "The role of HIV and monocytes/macrophages in adipose tissue biology." J. Acquir. Immune Defic. Syndr.. 2014;65(2):151-9.
Shikuma CM, Ribaudo HJ, Zheng Y, et al. "Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals." AIDS Res. Hum. Retroviruses. 2011;27(5):461-8.
Shire NJ, Rao MB, Succop P, et al. "Improving noninvasive methods of assessing liver fibrosis in patients with hepatitis C virus/human immunodeficiency virus co-infection." Clin. Gastroenterol. Hepatol.. 2009;7(4):471-80, 480.e1-2.
Shivakoti R, Christian P, Yang W-T, et al. "Prevalence and risk factors of micronutrient deficiencies pre- and post-antiretroviral therapy (ART) among a diverse multicountry cohort of HIV-infected adults." Clin Nutr. 2016;35(1):183-9.
Shivakoti R, Gupte N, Yang W-T, et al. "Pre-antiretroviral therapy serum selenium concentrations predict WHO stages 3, 4 or death but not virologic failure post-antiretroviral therapy." Nutrients. 2014;6(11):5061-78.
Shivakoti R, Yang W-T, Berendes S, et al. "Persistently Elevated C-Reactive Protein Level in the First Year of Antiretroviral Therapy, Despite Virologic Suppression, Is Associated With HIV Disease Progression in Resource-Constrained Settings." J. Infect. Dis.. 2016;213(7):1074-8.
Shivakoti R, Yang W-T, Gupte N, et al. "Concurrent Anemia and Elevated C-Reactive Protein Predicts HIV Clinical Treatment Failure, Including Tuberculosis, After Antiretroviral Therapy Initiation." Clin. Infect. Dis.. 2015;61(1):102-10.

Pages